PL3087095T3 - Antagoniści fcrn i sposoby stosowania - Google Patents

Antagoniści fcrn i sposoby stosowania

Info

Publication number
PL3087095T3
PL3087095T3 PL14827372T PL14827372T PL3087095T3 PL 3087095 T3 PL3087095 T3 PL 3087095T3 PL 14827372 T PL14827372 T PL 14827372T PL 14827372 T PL14827372 T PL 14827372T PL 3087095 T3 PL3087095 T3 PL 3087095T3
Authority
PL
Poland
Prior art keywords
methods
fcrn antagonists
fcrn
antagonists
Prior art date
Application number
PL14827372T
Other languages
English (en)
Inventor
Peter Ulrichts
Christophe Blanchetot
Torsten Dreier
Johannes De Haard
E. Sally Ward Ober
Nicolas G.H. Ongenae
Original Assignee
Argenx Bvba
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52347464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3087095(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Argenx Bvba, The Board Of Regents Of The University Of Texas System filed Critical Argenx Bvba
Publication of PL3087095T3 publication Critical patent/PL3087095T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
PL14827372T 2013-12-24 2014-12-23 Antagoniści fcrn i sposoby stosowania PL3087095T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920547P 2013-12-24 2013-12-24
PCT/US2014/072087 WO2015100299A1 (en) 2013-12-24 2014-12-23 Fcrn antagonists and methods of use
EP14827372.5A EP3087095B1 (en) 2013-12-24 2014-12-23 Fcrn antagonists and methods of use

Publications (1)

Publication Number Publication Date
PL3087095T3 true PL3087095T3 (pl) 2020-03-31

Family

ID=52347464

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14827372T PL3087095T3 (pl) 2013-12-24 2014-12-23 Antagoniści fcrn i sposoby stosowania

Country Status (26)

Country Link
US (3) US10316073B2 (pl)
EP (2) EP3087095B1 (pl)
JP (2) JP6554473B2 (pl)
KR (3) KR102452173B1 (pl)
CN (2) CN112142843B (pl)
AU (1) AU2014369999B2 (pl)
BR (1) BR112016014810B1 (pl)
CA (1) CA2934644C (pl)
DK (1) DK3087095T3 (pl)
EA (1) EA035324B1 (pl)
ES (1) ES2742682T3 (pl)
FI (1) FIC20230003I1 (pl)
FR (1) FR23C1004I2 (pl)
HU (2) HUE046822T2 (pl)
IL (1) IL246223B (pl)
LT (2) LT3087095T (pl)
LU (1) LUC00284I2 (pl)
MX (1) MX368804B (pl)
NL (1) NL301203I2 (pl)
NO (1) NO2022049I1 (pl)
NZ (1) NZ722055A (pl)
PL (1) PL3087095T3 (pl)
PT (1) PT3087095T (pl)
SG (2) SG11201605203UA (pl)
WO (1) WO2015100299A1 (pl)
ZA (2) ZA201604464B (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3087095T3 (pl) 2013-12-24 2020-03-31 Argenx Bvba Antagoniści fcrn i sposoby stosowania
ES2882999T3 (es) * 2015-03-09 2021-12-03 Argenx Bvba Métodos para reducir los niveles séricos de agentes que contienen Fc mediante el uso de antagonistas de FcRn
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
CN106957364B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb12及其应用
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
CA3045797A1 (en) 2016-12-02 2018-06-07 The Texas A&M University System Fusion proteins for selectively depleting antigen-specific antibodies
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
SG11202003980PA (en) 2017-10-31 2020-05-28 Staten Biotechnology B V Anti-apoc3 antibodies and methods of use thereof
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
MY209122A (en) * 2018-06-08 2025-06-23 argenx BV Compositions and methods for treating immune thrombocytopenia
AU2019307959B2 (en) * 2018-07-20 2025-09-25 Momenta Pharmaceuticals, Inc. FcRn antibody compositions
WO2020054979A1 (ko) * 2018-09-12 2020-03-19 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
CN114126647A (zh) * 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
TWI869542B (zh) * 2020-02-10 2025-01-11 大陸商北京拓界生物醫藥科技有限公司 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途
CN113769058B (zh) * 2020-06-10 2024-09-06 上海宝济药业股份有限公司 一种药物组合及其应用
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4359432A2 (en) 2021-06-23 2024-05-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Short apoc-ii mimetic peptides and methods of use
AU2023208882A1 (en) 2022-01-18 2024-05-09 argenx BV Galectin-10 antibodies
CN119923273A (zh) 2022-02-21 2025-05-02 阿根思有限公司 用于使用FcRn拮抗剂治疗肌炎的方法
CN119013290A (zh) 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
CN119233984A (zh) 2022-05-05 2024-12-31 美国政府(由卫生和人类服务部的部长所代表) 短载脂蛋白e模拟肽及其使用方法
CA3258004A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/HSA BONDING MOLECULES AND METHODS OF USE
CN115645537A (zh) * 2022-10-25 2023-01-31 成都臻拓医药科技有限公司 FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途
JP2025537777A (ja) * 2022-11-14 2025-11-20 アルジェニクス ビーブイ ＦｃＲｎアンタゴニスト分子及びそれらの使用方法
IL322228A (en) 2023-02-04 2025-09-01 Momenta Pharmaceuticals Inc Compositions and methods for treating hemolytic disease of the fetus and newborn
EP4665755A1 (en) 2023-02-17 2025-12-24 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
AU2024242538A1 (en) * 2023-03-24 2025-10-30 Paragon Therapeutics, Inc. Fc fragments that bind fcrn and methods of use
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025017368A1 (en) 2023-07-16 2025-01-23 argenx BV Methods of treating chronic inflammatory demyelinating polyneuropathy
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia
WO2025229224A1 (en) 2024-05-03 2025-11-06 argenx BV Monovalent anti-iga binding molecules and methods of use
WO2025233684A1 (en) 2024-05-10 2025-11-13 argenx BV Subcutaneous formulations, pre-filled syringes and methods of use thereof
WO2025233685A1 (en) 2024-05-10 2025-11-13 argenx BV Intravenous fcrn antagonist formulations and methods of use thereof
CN119490588B (zh) * 2024-10-17 2026-03-06 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
EP0805628B1 (en) 1995-01-17 2003-05-02 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
AU2002220404A1 (en) 2000-11-20 2002-05-27 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP3945281B2 (ja) 2002-03-19 2007-07-18 富士ゼロックス株式会社 画像形成装置
EP1513554B9 (en) 2002-05-30 2011-11-09 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
AU2004204462B2 (en) 2003-01-09 2012-03-08 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2052713A3 (en) 2003-01-13 2009-05-20 Macrogenics, Inc. Soluble FcgammaR fusion proteins and methods of use thereof
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
JP4281800B2 (ja) 2004-09-30 2009-06-17 ブラザー工業株式会社 無線タグ通信装置、無線タグ、無線通信システム、及び無線通信方法
EP1879920A2 (en) * 2005-04-29 2008-01-23 The Jackson Laboratory Fcrn antibodies and uses thereof
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
MX367012B (es) * 2007-06-01 2019-08-02 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
US8732170B2 (en) 2007-11-27 2014-05-20 Zettics, Inc. Method and apparatus for real-time multi-dimensional reporting and analyzing of data on application level activity and other user information on a mobile data network
US9260525B2 (en) * 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
AU2009238605B2 (en) 2008-04-25 2014-11-06 Biogen Idec Hemophilia Inc. Antibodies against FcRn and use thereof
US20100048488A1 (en) 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
CN102666874B (zh) 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
AU2011282579B2 (en) * 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
GB201111291D0 (en) 2011-06-30 2011-08-17 Agco Int Gmbh Engine control system
WO2013063186A2 (en) 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
WO2013074598A1 (en) * 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
SI2870247T1 (sl) 2012-07-05 2019-10-30 Hoffmann La Roche Ekspresijski in sekrecijski sistem
GB201302878D0 (en) 2013-02-19 2013-04-03 Argen X Bv Modified igG molecules
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
WO2015081073A2 (en) 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions and methods for modulating an immune response
PL3087095T3 (pl) 2013-12-24 2020-03-31 Argenx Bvba Antagoniści fcrn i sposoby stosowania
EP3193930B1 (en) 2014-09-17 2019-06-19 Affibody AB New polypeptides
PL3250610T3 (pl) 2015-01-30 2024-01-29 Momenta Pharmaceuticals, Inc. Przeciwciała anty-FcRn i sposoby ich stosowania
ES2882999T3 (es) 2015-03-09 2021-12-03 Argenx Bvba Métodos para reducir los niveles séricos de agentes que contienen Fc mediante el uso de antagonistas de FcRn
AU2016262100B2 (en) 2015-05-12 2021-10-14 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
JP7118884B2 (ja) 2015-07-17 2022-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
GB201618424D0 (en) 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
MY209122A (en) 2018-06-08 2025-06-23 argenx BV Compositions and methods for treating immune thrombocytopenia
US20220298241A1 (en) 2019-05-17 2022-09-22 Alexion Pharmaceuticals, Inc. Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases
CN114126647A (zh) * 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂

Also Published As

Publication number Publication date
DK3087095T3 (da) 2019-10-28
SG10202009832XA (en) 2020-11-27
IL246223A0 (en) 2016-07-31
KR20160111937A (ko) 2016-09-27
BR112016014810B1 (pt) 2023-12-26
US11505585B2 (en) 2022-11-22
CN112142843B (zh) 2024-10-18
HUS2200048I1 (hu) 2022-12-28
ZA202409972B (en) 2025-09-25
FIC20230003I1 (fi) 2023-01-19
AU2014369999B2 (en) 2019-12-12
WO2015100299A1 (en) 2015-07-02
ZA201604464B (en) 2025-05-28
LUC00284I2 (pl) 2025-05-12
NZ722055A (en) 2020-02-28
EP3087095B1 (en) 2019-08-07
MX2016008399A (es) 2016-12-15
FR23C1004I1 (fr) 2023-03-10
KR20240033084A (ko) 2024-03-12
JP2019076103A (ja) 2019-05-23
SG11201605203UA (en) 2016-07-28
CA2934644C (en) 2023-11-21
LTPA2022014I1 (pl) 2022-12-12
AU2014369999A1 (en) 2016-07-07
NL301203I2 (nl) 2023-05-24
CN106103476A (zh) 2016-11-09
JP6554473B2 (ja) 2019-07-31
CN112142843A (zh) 2020-12-29
NO2022049I1 (no) 2022-11-23
CA2934644A1 (en) 2015-07-02
US10316073B2 (en) 2019-06-11
NL301203I1 (pl) 2022-11-09
US20150218239A1 (en) 2015-08-06
LTC3087095I2 (pl) 2024-03-12
EA201691304A1 (ru) 2016-10-31
KR102452173B1 (ko) 2022-10-17
PT3087095T (pt) 2019-10-09
EP3626738A1 (en) 2020-03-25
EP3087095A1 (en) 2016-11-02
MX368804B (es) 2019-10-17
KR20220152546A (ko) 2022-11-16
US20180179258A1 (en) 2018-06-28
HUE046822T2 (hu) 2020-03-30
FR23C1004I2 (fr) 2024-01-05
IL246223B (en) 2021-06-30
US20220275035A1 (en) 2022-09-01
BR112016014810A2 (pt) 2017-09-19
LT3087095T (lt) 2019-09-10
EA035324B1 (ru) 2020-05-28
CN106103476B (zh) 2020-11-27
JP2017501725A (ja) 2017-01-19
ES2742682T3 (es) 2020-02-17

Similar Documents

Publication Publication Date Title
HUS2200048I1 (hu) FcRn antagonisták és alkalmazásaik
IL290547A (en) Antibodies and methods of use
IL280155A (en) Anti- SIGLEC-8 antibodies and methods of using them
TWI560180B (en) Substituted benzamides and methods of use thereof
IL244495A0 (en) Anti-alpha-synuclein antibodies and methods of use
IL240216A0 (en) Converted xanthines and methods of using them
IL244643A0 (en) Anti-ly6e antibodies and methods of use
HUE039624T2 (hu) Heterociklusos vegyületek és alkalmazási eljárások
IL242818B (en) Il-1beta-il-1ra chimera and methods of using the same